AwesomeCapital
Search This Blog
Friday, December 13, 2024
Checkpoint Therapeutics FDA OK of UNLOXCYT for squamous cell carcinoma
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
https://www.globenewswire.com/news-release/2024/12/13/2997087/36989/en/Checkpoint-Therapeutics-Announces-FDA-Approval-of-UNLOXCYT-cosibelimab-ipdl.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.